Insider · CIK 0001877242
Kaitlyn Arsenault
cfoofficer
Files at SKYE (Skye Bioscience, Inc.). First filing Nov 19, 2024, latest Nov 19, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $217k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SKYE: Skye Bioscience, Inc.
SKYEOct 9, 2026 · close 1.69
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 54Moderate | Skye Bioscience, Inc. | $217k 43,396 shares | -21% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Feb 9, 2026 |
| Feb 24, 2025 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Feb 26, 2025 |
| Nov 15, 2024 | SKYE Skye Bioscience, Inc. | SOpen-market sale Common Stock | -190 | $5.55 | $1,055 | 209,548 | Nov 19, 2024 |
| Nov 18, 2024 | SKYE Skye Bioscience, Inc. | SOpen-market sale Common Stock | -43,206 | $4.99 | $216k | 166,342 | Nov 19, 2024 |
| Oct 28, 2024 | SKYE Skye Bioscience, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Oct 30, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.